N-methyl-2-({3-[(E)-2-(pyridin-2-yl)ethenyl]-1H-indazol-6-yl}sulfanyl)benzamide
| Title | Journal |
|---|---|
| BET Bromodomain Suppression Inhibits VEGF-induced Angiogenesis and Vascular Permeability by Blocking VEGFR2-mediated Activation of PAK1 and eNOS. | Scientific reports 20160101 |
| Bridging Functional and Structural Cardiotoxicity Assays Using Human Embryonic Stem Cell-Derived Cardiomyocytes for a More Comprehensive Risk Assessment. | Toxicological sciences : an official journal of the Society of Toxicology 20151101 |
| The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents. | Journal of medicinal chemistry 20150108 |
| The discovery of PLK4 inhibitors: (E)-3-((1H-Indazol-6-yl)methylene)indolin-2-ones as novel antiproliferative agents. | Journal of medicinal chemistry 20130808 |
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. | Pancreas 20130401 |
| Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours. | British journal of cancer 20121009 |
| Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours. | British journal of cancer 20121009 |
| Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation. | Journal of pharmaceutical sciences 20121001 |
| Axitinib, a new therapeutic option in renal cell carcinoma. | Drugs of today (Barcelona, Spain : 1998) 20121001 |
| Case of complete response to everolimus for metastatic renal cell carcinoma. | International journal of urology : official journal of the Japanese Urological Association 20120901 |
| [Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects]. | Magyar onkologia 20120901 |
| Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer. | Investigational new drugs 20120801 |
| Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma. | Japanese journal of clinical oncology 20120801 |
| Concise drug review: pazopanib and axitinib. | The oncologist 20120801 |
| Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. | Cancer chemotherapy and pharmacology 20120701 |
| Axitinib (Inlyta) for advanced renal cell carcinoma. | The Medical letter on drugs and therapeutics 20120611 |
| Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. | Investigational new drugs 20120601 |
| Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. | Melanoma research 20120601 |
| Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns. | Clinical genitourinary cancer 20120601 |
| [Therapeutic effect of axitinib and 5-FU in nude mice bearing human colon cancer xenograft]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20120601 |
| Novel molecular targeted therapies for refractory thyroid cancer. | Head & neck 20120501 |
| Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. | European journal of clinical pharmacology 20120501 |
| Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. | Clinical advances in hematology & oncology : H&O 20120501 |
| Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. | Cancer discovery 20120401 |
| Evaluation of drugs with specific organ toxicities in organ-specific cell lines. | Toxicological sciences : an official journal of the Society of Toxicology 20120301 |
| VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. | Cancer research 20120301 |
| [Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors]. | Magyar onkologia 20120301 |
| Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. | Investigational new drugs 20120201 |
| Axitinib modulates hypoxia-induced blood-retina barrier permeability and expression of growth factors. | Growth factors (Chur, Switzerland) 20120201 |
| Pharmacokinetic evaluation of axitinib. | Expert opinion on drug metabolism & toxicology 20120201 |
| Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report. | Anticancer research 20120201 |
| Drug approvals 2011: focus on companion diagnostics. | Journal of the National Cancer Institute 20120118 |
| An update on targeted therapy in metastatic renal cell carcinoma. | Urologic oncology 20120101 |
| VEGF-induced growth cone enhancement is diminished by inhibiting tyrosine-residue 1214 of VEGFR-2. | Cells, tissues, organs 20120101 |
| Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. | Molecular medicine (Cambridge, Mass.) 20120101 |
| Peginesatide acetate, axitinib, and pertuzumab. | Journal of the American Pharmacists Association : JAPhA 20120101 |
| Tilting the AXIS towards therapeutic limits in renal cancer. | Lancet (London, England) 20111203 |
| Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. | Lancet (London, England) 20111203 |
| Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics. | Investigational new drugs 20111201 |
| Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20111201 |
| Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. | European journal of cancer (Oxford, England : 1990) 20111101 |
| A Phase I study to evaluate the pharmacokinetics of axitinib (AG-13736) in healthy Chinese volunteers. | International journal of clinical pharmacology and therapeutics 20111101 |
| Axitinib in the treatment of metastatic renal cell carcinoma. | Future oncology (London, England) 20111101 |
| Comprehensive analysis of kinase inhibitor selectivity. | Nature biotechnology 20111030 |
| Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS. | Clinical genitourinary cancer 20110901 |
| Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620 |
| Anti-vascular endothelial growth factor therapy for breast cancer: can we pick the winners? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20110620 |
| The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. | International journal of cancer 20110601 |
| Rapid identification and absence of drug tests for AG-013736 in 1mg Axitinib tablets by ion mobility spectrometry and DART™ mass spectrometry. | Journal of pharmaceutical and biomedical analysis 20110601 |
| The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells. | The Journal of clinical endocrinology and metabolism 20110601 |
| Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110601 |
| Axitinib for the management of metastatic renal cell carcinoma. | Drugs in R&D 20110601 |
| Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. | Drug metabolism and disposition: the biological fate of chemicals 20110501 |
| Antiangiogenesis enhances intratumoral drug retention. | Cancer research 20110401 |
| Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. | The Lancet. Oncology 20110301 |
| Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. | Neoplasia (New York, N.Y.) 20110301 |
| A thermodynamic-based approach to analyzing a highly solvating polymorphic system: the desolvation window method. | Journal of pharmaceutical sciences 20110101 |
| Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. | Chemistry & biology 20101124 |
| Phase Ib study of CP-868,596, a PDGFR inhibitor, combined with docetaxel with or without axitinib, a VEGFR inhibitor. | British journal of cancer 20101109 |
| Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. | European journal of medicinal chemistry 20101101 |
| Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? | Expert review of anticancer therapy 20101001 |
| Development of a targeted polymorph screening approach for a complex polymorphic and highly solvating API. | Journal of pharmaceutical sciences 20100901 |
| Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. | Cancer science 20100401 |
| Molecular therapy of pancreatic cancer. | Minerva endocrinologica 20100301 |
| Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. | Cancer chemotherapy and pharmacology 20100201 |
| A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. | Annals of oncology : official journal of the European Society for Medical Oncology 20100201 |
| Compounds in clinical Phase III and beyond. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101 |
| Axitinib (AG-013736). | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101 |
| Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20091215 |
| Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes. | Cancer treatment reviews 20091201 |
| Axitinib--a selective inhibitor of the vascular endothelial growth factor (VEGF) receptor. | Targeted oncology 20091201 |
| Tyrosine kinase inhibitors and the thyroid. | Best practice & research. Clinical endocrinology & metabolism 20091201 |
| Targeted molecular therapies in thyroid carcinoma. | Arquivos brasileiros de endocrinologia e metabologia 20091201 |
| CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. | British journal of cancer 20091006 |
| Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090920 |
| Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090810 |
| Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib. | Biochemistry 20090728 |
| Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors. | Cancer research 20090515 |
| Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma. | Cancer 20090515 |
| Targeted therapies in metastatic renal cancer in 2009. | BJU international 20090501 |
| Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response. | Radiation research 20090501 |
| Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090120 |
| Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. | Clinical cancer research : an official journal of the American Association for Cancer Research 20090115 |
| Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. | Clinical cancer research : an official journal of the American Association for Cancer Research 20081115 |
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20081010 |
| Novel drugs for renal cell carcinoma. | Expert opinion on investigational drugs 20081001 |
| von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. | The Journal of urology 20080901 |
| [Tumor vasculature as a therapeutic target in non-small cell lung cancer]. | Magyar onkologia 20080901 |
| Targeting angiogenesis in pancreatic cancer. | Lancet (London, England) 20080621 |
| Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. | Lancet (London, England) 20080621 |
| Early clinical studies of novel therapies for thyroid cancers. | Endocrinology and metabolism clinics of North America 20080601 |
| Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors. | Current opinion in investigational drugs (London, England : 2000) 20080601 |
| Axitinib for renal cell carcinoma. | Expert opinion on investigational drugs 20080501 |
| Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. | Molecular cancer therapeutics 20080101 |
| Health-related quality of life during treatment for renal cell carcinoma: results from a phase II study of axitinib. | Acta oncologica (Stockholm, Sweden) 20080101 |
| Signaling inhibitors in metastatic renal cell carcinoma. | Cancer journal (Sudbury, Mass.) 20080101 |
| Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. | The Lancet. Oncology 20071101 |
| Targeting VEGF receptors in kidney cancer. | The Lancet. Oncology 20071101 |
| The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. | Cancer research 20071015 |
| Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. | Cancer 20070801 |
| American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3. | IDrugs : the investigational drugs journal 20070801 |
| [Oral drugs inhibiting the VEGF pathway]. | Bulletin du cancer 20070701 |
| AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. | Magnetic resonance imaging 20070401 |
| Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20070115 |
| Rationale and clinical results of multi-target treatments in oncology. | The International journal of biological markers 20070101 |
| Rapid vascular regrowth in tumors after reversal of VEGF inhibition. | The Journal of clinical investigation 20061002 |
| Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. | BJU international 20061001 |
| New treatment approaches in metastatic renal cell carcinoma. | Current opinion in urology 20060901 |
| The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | Leukemia research 20060701 |
| Molecular targeting therapy for renal cell carcinoma. | International journal of clinical oncology 20060601 |
| VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. | Current oncology reports 20060301 |
| Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. | Cancer research 20060301 |
| Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. | American journal of physiology. Heart and circulatory physiology 20060201 |
| VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. | American journal of physiology. Heart and circulatory physiology 20060201 |
| Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. | Cancer research 20060201 |
| [Progress in therapeutic strategy for renal cell carcinoma]. | Gan to kagaku ryoho. Cancer & chemotherapy 20060201 |
| SU11248 and AG013736: current data and future trials in renal cell carcinoma. | Clinical genitourinary cancer 20051201 |
| Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. | Journal of magnetic resonance imaging : JMRI 20051001 |
| Imaging and other biomarkers in early clinical studies: one step at a time or re-engineering drug development? | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820 |
| Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20050820 |
| Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. | The American journal of pathology 20040701 |